Post-hoc analysis of the HOPE trial demonstrated a 32% reduction in the incidence of development of new-onset diabetes (insulin resistance and hyperglycemia) in patients treated with the ACE inhibitor, ramapril. The gene discussed is ACE; the disease is Hyperglycemia.